Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,703.0 02/08/16
52 week low1,339.5 12/07/17
52 week change -1,136.0 (-45.04%)
4 week volume9,270,744 28/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 8851L Hikma Pharmaceuticals Plc 24 July 2017 Notification of major interests in shares LONDON, 24 July 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of e...

Total Voting Rights

RNS Number: 0660K Hikma Pharmaceuticals Plc 04 July 2017 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 4 July 2017, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 240,647,229 ordinary shares with voting rights. There are nil shares held in treas...

Holding(s) in Company

RNS Number: 9623J Hikma Pharmaceuticals Plc 03 July 2017 Notification of major interests in shares LONDON, 3 July 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows: 1 Identity of the issuer or the underlying issuer of existing shares to which the voting rights are at...

Holding(s) in Company

RNS Number: 8024J Hikma Pharmaceuticals Plc 30 June 2017 Notification of major interests in shares LONDON, 30 June 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of ...

Broker Forecast - HSBC issues a broker note on Hikma Pharmaceuticals PLC

HSBC today reaffirms its reduce investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to ...

Hikma's US CEO to retire

Hikma Pharmaceuticals has announced the planned retirement of the chief executive of its US business, Michael Raya. Hi...

Leadership and Structural Changes to US Business

RNS Number: 0778J Hikma Pharmaceuticals Plc 26 June 2017 Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business London, 26 June 2017 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the fast-growing multinational pharmaceutica...

The week ahead: Big day for Sirius Minerals

The FTSE reshuffle takes effect Monday, while investors get an update from a retailer just days after grim retail sales data...

Fundamental DataMore

P/E ratio20.842
EPS66.5
Dividend yield2.381 %

Latest discussion posts More

  • ADVFN/M&A

    4 YEAR LOWS HERE. You have to go back to late 2013-14 to see the SP at these levels. For no good reason either. Yet another shorter orchestrated fall. 5.31% Aside from ...
    5-Jul-2017
    Thedarkkn1ght
  • Re: SP Slide

    broker downgrade today but only the reason for todays fall
    28-Jun-2017
    paul1945
  • SP Slide

    Since the drop out of ftse 100 the sp fall has continued, is the problem with FDA the problem?
    28-Jun-2017
    Hawk Eye32

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..
LLOYDS GRP.34%
RDS 'B'25%
GLAXOSMITHKLINE24%
BP23%
BT GROUP23%

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK